Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H2 2016', provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) 
- The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) Overview 7
Therapeutics Development 8
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Products under Development by Stage of Development 8
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Products under Development by Therapy Area 9
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Products under Development by Indication 10
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Products Glance 11
Early Stage Products 11
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Products under Development by Companies 12
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Products under Development by Universities/Institutes 14
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Amgen Inc. 22
AstraZeneca Plc 23
Complix NV 24
Les Laboratoires Servier SAS 25
Takeda Pharmaceutical Company Limited 26
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles 27
AMG-176 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
FL-118 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Proteins to Inhibit MCL-1 for Oncology - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
S-63845 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit MCL-1 for Cancer - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit Mcl-1 for Non Small Cell Lung Cancer and Multiple Myeloma - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
UMI-77 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Projects 42
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Featured News & Press Releases 45
Oct 20, 2016: New compound shows promise in treating multiple human cancers 45
Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies 46
Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer 46
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 48
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 49
Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent 49
Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by AbbVie Inc, H2 2016 21
Pipeline by Amgen Inc., H2 2016 22
Pipeline by AstraZeneca Plc, H2 2016 23
Pipeline by Complix NV, H2 2016 24
Pipeline by Les Laboratoires Servier SAS, H2 2016 25
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 26
Dormant Projects, H2 2016 42
Dormant Projects (Contd..1), H2 2016 43
Dormant Projects (Contd..2), H2 2016 44